Home LiteratureArticle Details
PMID: 22190941 Published · ppublish English Journal Article

Clinical Application of Mesenchymal Stem Cells in the Treatment and Prevention of Graft-versus-Host Disease.

Advances in hematology ·Vol. 2011 ·2011-00-00 ·Pages 427863

Lin Y, Hogan WJ

Abstract

Mesenchymal stem cells (MSCs) represent a heterogeneous population of stromal cells with pluripotent mesenchymal differentiation potential. They have been found to have immunosuppressive properties and the ability to modulate angiogenesis and endogenous tissue repair by in vitro and animal studies. Clinical trials have examined the utility of these cells in autoimmune and inflammatory conditions. In particular, in allogeneic hematopoietic stem cell transplant (HSCT), multiple studies have been conducted to explore the use of MSC to treat acute and chronic graft-versus-host disease (GVHD) and for cotransplantation with HSCT to promote HSC engraftment and prevent GVHD. We review here the results of these studies and discuss some challenges of this treatment modality in this disease setting.

Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Lin Yi
Division of Hematology, Department of Medicine, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA.
Hogan William J
References (46)
46 references, click to expand
  1. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease.
    Eur J Immunol. 2008 Jun;38(6):1745-55 PMID: 18493986
  2. Graft-versus-host disease.
    Lancet. 2009 May 2;373(9674):1550-61 PMID: 19282026
  3. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells.
    Leukemia. 2007 Aug;21(8):1733-8 PMID: 17541394
  4. Human mesenchymal stem cells and immunosuppressive drug interactions in allogeneic responses: an in vitro study using human cells.
    Transplant Proc. 2009 Oct;41(8):3347-52 PMID: 19857747
  5. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli.
    Blood. 2002 May 15;99(10):3838-43 PMID: 11986244
  6. Human marrow-derived mesenchymal stem cells (MSCs) express hematopoietic cytokines and support long-term hematopoiesis when differentiated toward stromal and osteogenic lineages.
    J Hematother Stem Cell Res. 2000 Dec;9(6):841-8 PMID: 11177595
  7. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
    Biol Blood Marrow Transplant. 2010 Jun;16(6):838-47 PMID: 20109568
  8. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells.
    Stem Cells. 2008 Jan;26(1):212-22 PMID: 17932417
  9. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation.
    Transplantation. 2003 Feb 15;75(3):389-97 PMID: 12589164
  10. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement.
    Cytotherapy. 2005;7(5):393-5 PMID: 16236628
  11. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells.
    J Immunol. 2008 Sep 15;181(6):3933-46 PMID: 18768848
  12. Treatment of high-risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype.
    Br J Haematol. 2002 Sep;118(4):1128-31 PMID: 12199796
  13. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study.
    Leukemia. 2008 Mar;22(3):593-9 PMID: 18185520
  14. Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: effects of dexamethasone and IL-1 alpha.
    J Cell Physiol. 1996 Mar;166(3):585-92 PMID: 8600162
  15. Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease.
    Transplant Proc. 2007 Dec;39(10):3358-62 PMID: 18089385
  16. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients.
    Biol Blood Marrow Transplant. 2005 May;11(5):389-98 PMID: 15846293
  17. Results of a pilot study on the use of third-party donor mesenchymal stromal cells in cord blood transplantation in adults.
    Cytotherapy. 2009;11(3):278-88 PMID: 19308773
  18. Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial.
    Haematologica. 2011 Jul;96(7):1072-6 PMID: 21393326
  19. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation.
    Blood. 2006 Feb 15;107(4):1484-90 PMID: 16239427
  20. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells.
    Lancet. 2004 May 1;363(9419):1439-41 PMID: 15121408
  21. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation.
    Blood. 2007 Oct 1;110(7):2764-7 PMID: 17638847
  22. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study.
    Lancet. 2008 May 10;371(9624):1579-86 PMID: 18468541
  23. Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: clinical report.
    Biol Blood Marrow Transplant. 2010 Mar;16(3):403-12 PMID: 19925878
  24. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells.
    Blood. 2005 May 15;105(10):4120-6 PMID: 15692068
  25. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.
    Cytotherapy. 2006;8(4):315-7 PMID: 16923606
  26. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo.
    Exp Hematol. 2002 Jan;30(1):42-8 PMID: 11823036
  27. Human mesenchymal stem cells modulate B-cell functions.
    Blood. 2006 Jan 1;107(1):367-72 PMID: 16141348
  28. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease.
    Transplantation. 2006 May 27;81(10):1390-7 PMID: 16732175
  29. Human mesenchymal stem cells modulate allogeneic immune cell responses.
    Blood. 2005 Feb 15;105(4):1815-22 PMID: 15494428
  30. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease.
    Stem Cells. 2006 Nov;24(11):2582-91 PMID: 16873762
  31. Single intra-arterial injection of mesenchymal stromal cells for treatment of steroid-refractory acute graft-versus-host disease: a pilot study.
    Cytotherapy. 2010 Apr;12(2):265-8 PMID: 19961282
  32. Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate.
    Transpl Immunol. 2008 Nov;20(1-2):55-60 PMID: 18762258
  33. Concise review: Mesenchymal stem cell tumor-homing: detection methods in disease model systems.
    Stem Cells. 2011 Jun;29(6):920-7 PMID: 21557390
  34. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice.
    J Immunol. 2006 Jun 15;176(12):7761-7 PMID: 16751424
  35. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression.
    Stem Cells. 2009 Aug;27(8):1954-62 PMID: 19544427
  36. Mesenchymal stem cells as therapeutics.
    Annu Rev Biomed Eng. 2010 Aug 15;12:87-117 PMID: 20415588
  37. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease.
    Biol Blood Marrow Transplant. 2009 Jul;15(7):804-11 PMID: 19539211
  38. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation.
    Blood. 2004 Jun 15;103(12):4619-21 PMID: 15001472
  39. Cotransplantation of HLA-identical mesenchymal stem cells and hematopoietic stem cells in Chinese patients with hematologic diseases.
    Int J Lab Hematol. 2010 Apr;32(2):256-64 PMID: 19656235
  40. Susceptibility of human mesenchymal stem cells to tacrolimus, mycophenolic acid, and rapamycin.
    Transplantation. 2008 Nov 15;86(9):1283-91 PMID: 19005411
  41. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms.
    Circ Res. 2004 Mar 19;94(5):678-85 PMID: 14739163
  42. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium.
    Bone Marrow Transplant. 2009 Feb;43(3):245-51 PMID: 18820709
  43. Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance.
    Am J Transplant. 2009 Aug;9(8):1760-72 PMID: 19563344
  44. Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation.
    Blood Cells Mol Dis. 2008 Jan-Feb;40(1):25-32 PMID: 17869550
  45. Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study.
    Biol Blood Marrow Transplant. 2011 Apr;17(4):534-41 PMID: 20457269
  46. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex.
    Scand J Immunol. 2003 Jan;57(1):11-20 PMID: 12542793
Article Info
Journal
Advances in hematology
Abbr.
Adv Hematol
ISSN
1687-9112
DOI
10.1155/2011/427863
Published
2011-00-00
Epub
2011-00-10
Pages
427863
Language
English
Region
United States
NLM ID
101504271
PMCID
PMC3235491
External Links
PubMed source DOI: 10.1155/2011/427863 PMC Full Text
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2